Uncategorized files

Showing below up to 50 results in range #39,121 to #39,170.

• 
  MaoriChief1784.jpg 455 × 599; 70 KB
  
• 
  Map-ebola-guinea-23032014.gif 450 × 510; 21 KB
  
• 
  Map-icon.png 128 × 128; 12 KB
  
• 
  Map.jpg 557 × 456; 63 KB
  
• 
  Map 3-06.png 2,825 × 1,800; 71 KB
  
• 
  Map Africa--Yellow Fever.jpg 153 × 200; 25 KB
  
• 
  Map South America--Yellow Fever.jpg 152 × 200; 22 KB
  
• 
  Map US rabies.jpg 500 × 331; 61 KB
  
• 
  Map WNV 807 07 a.jpg 363 × 220; 30 KB
  
• 
  Map epidemia Ehrlichiosis.gif 415 × 261; 8 KB
  
• 
  Map human ehrlichiosis.gif 442 × 297; 32 KB
  
• 
  Map of Japanese encephalitis.jpg 600 × 541; 60 KB
  
• 
  Map of distribution.jpg 555 × 429; 58 KB
  
• 
  Map of skin hue equi3.png 750 × 293; 84 KB
  
• 
  Map rabies.jpg 449 × 297; 57 KB
  
• 
  Map s.jpg 557 × 456; 63 KB
  
• 
  Map yersinia.jpg 1,200 × 654; 268 KB
  
• 
  Mapap NDC 09041982.jpg 640 × 480; 22 KB
  
• 
  Mapro5.jpg 1,026 × 2,824; 501 KB
  
• 
  Maprotiline Hydrochloride NDC 03780060.jpg 640 × 480; 21 KB
  
• 
  Maprotiline Hydrochloride NDC 03780087.jpg 640 × 480; 29 KB
  
• 
  Maprotiline Hydrochloride NDC 03780092.jpg 640 × 480; 54 KB
  
• 
  Mar07 090.jpg 1,021 × 638; 46 KB
  
• 
  Maralixbat Drug Information.png 966 × 1,516; 325 KB
  
• 
  Maralixbat Structure.png 578 × 580; 42 KB
  
• 
  Maralixibat Drug Label (30 mL).png 1,328 × 482; 532 KB
  
• 
  Maralixibat Structure 2.png 700 × 358; 82 KB
  
• 
  Maralixibat Table 1 Dosage Info.png 1,226 × 1,290; 171 KB
  
• 
  Maralixibat Table 2 Adverse Reactions.png 686 × 1,404; 330 KB
  
• 
  Maralixibat Table 3 Clinical Trial Data.png 1,006 × 624; 101 KB
  
• 
  Marantic endocarditis in Pancreas Ca.jpg 800 × 471; 248 KB
  
• 
  Maraviroc 150 mg.png 635 × 255; 178 KB
  
• 
  Maraviroc 150 mg FDA package label.png 626 × 1,250; 112 KB
  
• 
  Maraviroc 300 mg.png 629 × 191; 142 KB
  
• 
  Maraviroc 300 mg FDA package label.png 625 × 1,349; 118 KB
  
• 
  Maraviroc Demographic and Baseline Characteristics of Subjects in Trial A4001026.png 628 × 717; 60 KB
  
• 
  Maraviroc Demographic and Baseline Characteristics of Subjects in Trials A4001027 and A4001028.png 624 × 1,653; 139 KB
  
• 
  Maraviroc Development of Resistance to Maraviroc or Efavirenz and Background Drugs in Antiretroviral Treatment-Naive Trial.png 629 × 481; 51 KB
  
• 
  Maraviroc Exposure Response Relationship in Treatment-Experienced Subjects.png 639 × 457; 46 KB
  
• 
  Maraviroc Exposure Response Relationship in Treatment-Naive Subjects.png 633 × 330; 25 KB
  
• 
  Maraviroc Laboratory Abnormalities.png 622 × 614; 57 KB
  
• 
  Maraviroc Mean Maraviroc Pharmacokinetic Parameters.png 623 × 516; 52 KB
  
• 
  Maraviroc Outcomes of Randomized Treatment at Week 48 Trials A4001027 and A4001028.png 627 × 698; 72 KB
  
• 
  Maraviroc Trial Outcome at Week 96 Using Enhanced Sensitivity Assay.png 638 × 1,201; 132 KB
  
• 
  Maraviroc Trial in Treatment‑Naive Subjects.png 624 × 2,084; 166 KB
  
• 
  Maraviroc Trials in Treatment-Experienced Subjects.png 626 × 2,954; 229 KB
  
• 
  Maraviroc structural formula.png 223 × 137; 14 KB
  
• 
  Maraviroc structure.png 265 × 230; 9 KB
  
• 
  Marbofloxacin.PNG 220 × 114; 7 KB
  
• 
  Marburg Hemorrhagic Virus.png 691 × 469; 292 KB